Committee Rejects FDA’s Proposed Treatment Target For ESAs
This article was originally published in The Pink Sheet Daily
Executive Summary
Hemoglobin target will depend on FDA’s acceptance of observational data to drive treatment.
You may also be interested in...
FDA Advisory Committee Will Review ESAs In The Renal Setting Oct. 18
Meeting also could be next step in the process of determining whether safety issues are enough to drive changes to erythropoiesis-stimulating agent reimbursement at CMS.
FDA Advisory Committee Will Review ESAs In The Renal Setting Oct. 18
Meeting also could be next step in the process of determining whether safety issues are enough to drive changes to erythropoiesis-stimulating agent reimbursement at CMS.
Roche Hedges On U.S. Launch Of Mircera With November FDA Action Date Expected
Decision in Amgen’s patent infringement case against Roche over the continuous erythropoiesis receptor activator is expected in October.